My research investigates the intersection of epigenetics, aging, and cancer, with a focus on how aberrant epigenetic modifications control cell fate. A central theme of our lab is that aging-like epigenetic alterations create a permissive state for tumorigenesis. Our work aims to elucidate this process and find ways to intervene.
Our research activities are structured around three core areas:
Identifying Driver Lesions: We use organoid models and multi-omics to discover and functionally validate key epigenetic changes and their target genes that drive both aging and cancer initiation.
Dissecting Driving Mechanisms: We explore the upstream causes, such as DNA damage and metabolic stress, that lead to the accumulation of these epigenetic errors over time.
Therapeutic Reprogramming: We develop and utilize advanced epigenome editing technologies to correct pathological epigenetic states, with the ultimate goal of reprogramming cell fate for therapeutic benefit in cancer/aging.
My research investigates the intersection of epigenetics, aging, and cancer, with a focus on how aberrant epigenetic modifications control cell fate. A central theme of our lab is that aging-like epigenetic alterations create a permissive state for tumorigenesis. Our work aims to elucidate this process and find ways to intervene.
Our research activities are structured around three core areas:
Identifying Driver Lesions: We use organoid models and multi-omics to discover and functionally validate key epigenetic changes and their target genes that drive both aging and cancer initiation.
Dissecting Driving Mechanisms: We explore the upstream causes, such as DNA damage and metabolic stress, that lead to the accumulation of these epigenetic errors over time.
Therapeutic Reprogramming: We develop and utilize advanced epigenome editing technologies to correct pathological epigenetic states, with the ultimate goal of reprogramming cell fate for therapeutic benefit in cancer/aging.